Investor Presentation

Here's a summary of the Q1FY26 earnings presentation: **1. Financial Highlights:** Q1FY26 total revenue INR 1,390.6 Cr, profit after tax INR 480.3 Cr, with 45.5% EBITDA margin and EPS of INR 26.84. Net cash INR 3,474.0 Cr. **2. Strategic Initiatives & Growth Drivers:** NATCO expands its US pipeline with over 20 Para IV FTF opportunities, including Ozempic.

Strategic investments: US$8 Mn in xenotransplantation, US$2 Mn in CAR-T/gene therapies (human dosing for Leukemia soon). A Phase 2 trial for its NCE (NRC-2694) in Head & Neck cancer is ongoing in the US and India. **3. Market Position, Business Developments & Competitive Advantage:** Export formulations drove 78.6% of Q1FY26 revenue, domestic 8.4%. The company's focus on complex generics (Para IV/FTF) for the US market provides a strategic edge.

Investments in novel drug discovery and advanced therapies (cell & gene therapy) solidify its innovative market standing. **4. Investor Implications:** Robust financials, an aggressive pipeline, and cutting-edge biotech investments signal positive long-term growth potential.

The dual focus on complex generics and innovation offers a competitive advantage; execution on NCE and cell therapy trials will be critical.